Discover trends, market shifts, and competitive outlooks for the ticovac global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
How Has The Ticovac Market Size Shifted, And What Is the Outlook Through 2034?
The ticovac market has experienced significant growth in its size over the past few years. It is projected to expand from a value of $4,010 million in 2024 to $4,310 million in 2025, presenting a compound annual growth rate (CAGR) of 7.6%. Factors contributing to this growth during the historical period include heightened awareness, a surge in travels to endemic regions, increasing veterinary issues, a growing elderly population, and an escalated rate in military and defense vaccinations.
The market for ticovac is anticipated to experience robust growth in the coming years. Its value is projected to reach $5,700 million by 2029, with a Compound Annual Growth Rate (CAGR) of 7.3%. The forecasted growth can be traced back to factors such as an increase in outdoor workers, heightened healthcare spending, a concentrated focus on controlling regional disease, an increase in health insurance coverage, and a growing number of tick-borne encephalitis (tbe) cases. The forecast period will also see key trends such as advancements in vaccine production technology, the development of new tbe vaccines, partnerships between governments and pharmaceutical corporations, improvements in genetic research, and progress in monitoring and aftercare post-vaccination.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19939&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Ticovac Market?
The escalating occurrence of diseases transmitted by ticks is anticipated to fuel the expansion of the ticovac market in the future. Such diseases are implicated from the bite of a tick that carries bacteria, viruses, or parasites, with climate change, tick habitat growth, increased human interaction, and improved diagnostics as catalysts. Ticovac is essential for these diseases as it offers active protection against tick-borne encephalitis (TBE), a serious viral infection from tick bites. For instance, in February 2024, the Centers for Disease Control and Prevention reported the overall Lyme disease incidence to be 18.9 cases per 100,000 population, a rate 68.8% higher than previous years. With high-incidence areas showing a median rate 58% higher at 68.3 cases per 100,000 and incidence for children aged 5–9 years at 16.5 cases per 100,000, reflecting an 11.5% increase. Thus, the growing occurrence of tick-borne diseases is propelling the ticovac market’s expansion. Growth in the ticovac market is anticipated due to heightened research and development endeavours. These activities encompass systematic exploration and innovation, geared towards the creation of new innovation or improving existing solutions or developing new technologies via scientific and technical research. An increasing demand for innovation, technological progress, and addressing emerging global challenges in various sectors are driving this rise. These activities benefit Ticovac by promoting progress in vaccine formulation and enhancing efficacy, enabling it to tackle emerging tick-borne encephalitis strains. For instance, in July 2024, the Department of Health and Social Care reported that the business enterprise sector had spent $11.3 billion (£9.0 billion) on pharmaceutical research and development in 2022, making up for 0.36% of the UK’s GDP. This comprised 18% of all business-driven R&D in the UK during that year, being the highest distribution across all product sectors. Therefore, the relatively high level of research and development activities contributes to the growth of the ticovac market.
Which Key Market Segments Comprise the Ticovac Market and Drive Its Revenue Growth?
The ticovacmarket covered in this report is segmented –
1) By Formulation: Inactivated Vaccines; Live Attenuated Vaccines
2) By Indication: Tick-Borne Encephalitis; Japanese Encephalitis; Rabies Encephalitis
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=19939&type=smp
Which Areas Are Leading Regions in the Ticovac Market Expansion Across the Globe?
Europe was the largest region in the ticovac market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Ticovac Market Over the Coming Years?
A significant trend in the ticovac market revolves around developing innovative formulations, such as suspension liquid, to secure a competitive advantage within the sector. Vaccine formulations using suspension liquid for thwarting tick-borne encephalitis, suitable for intramuscular injection, are currently in focus. This vaccine is available in a dose of 0.5 mL and is applicable for both adults and children. For instance, in September 2024, Pfizer Inc., a US-based pharmaceutical company, introduced Ticovac, a vaccine created to prevent tick-borne encephalitis (TBE), a viral infection impacting the brain and spinal cord. This vaccine, first of its kind in Japan, provides protection against the disease in endemic areas. The vaccine is made available in two forms, one for adults and another for children, both being a 0.5 mL intramuscular injection.
View the full report here:
https://www.thebusinessresearchcompany.com/report/ticovac-global-market-report-
How Is the Ticovac Market Conceptually Defined?
TicoVac is a vaccine used to protect against tick-borne encephalitis (TBE), a viral disease transmitted primarily through tick bites or, less commonly, by consuming unpasteurized dairy products from infected animals. TBE affects the central nervous system and can lead to severe neurological complications, including meningitis and encephalitis. TicoVac works by stimulating the immune system to recognize and fight the tick-borne encephalitis virus (TBEV) if exposed in the future.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19939
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model